Abstract
Overview
Introduction
The ALS market was worth $148m in 2006 across the seven major markets. With
the only approved treatment for ALS, Sanofi-Aventis' s Rilutek (riluzole),
facing generic incursion in 2012-13, future growth in this market is dependent
on the success of pipeline drugs.
Scope
- Scenario based analysis and forecasts of the commercial potential of the
ALS market to 2016.
- Analysis of patient potential, marketing factors, commercial
attractiveness and clinical attractiveness of key late-stage pipeline drugs.
- Strategic recommendations for maximizing the potential of drugs in this
niche orphan disease market.
- Indication-specific sales forecasts of marketed and key pipeline drugs to
2016.
Report Highlights
A lack of new entrants, and the possibility of polytherapy, results in
Sanofi-Aventis' s Rilutek (riluzole) dominating the market until patent expiry
in 2012-13 in Datamonitor' s base scenario.
Orphan drug status, rapid uptake following launch, limited risk to the
company' s share price if drugs fail, and possible indication expansions make
long-term investment in ALS a commercially viable option.
A scenario forecast based on the clinical success of rhIGF-1 (recombinant
human insulin-like growth factor I) related therapies reveals a potentially
lucrative market. However, with a high attrition rate of ALS Phase III
clinical trials, and mixed efficacy data in Phase II, the results of currently
underway studies will be pivotal.
Reasons to Purchase
- Access the lucrative potential of this underdeveloped neurodegenerative
disease therapeutic market.
- Benchmark key late-stage compounds against the current leading therapy
Sanofi-Aventis' s Rilutek (riluzole).
- Understand the opportunities in this market based on the comments of
interviewed key opinion leaders.
| 
View Cart
